关键词:

 , 缺血 / 再灌注损伤 , 无缺血肝移植 , 肝细胞癌复发

Abstract:

Objective The purpose of this study is to evaluate the potential effect of ischemia-free liver transplantation（IFLT）technology in reducing the recurrence of hepatocellular carcinoma（HCC）after liver transplantation，and to compare it with the outcomes of conventional liver transplantation（CLT）. Methods We conducted a retrospective cohort study，including 208 HBV-HCC patients who underwent liver transplantation at the First Affiliated Hospital of Sun Yat-sen University from January 1，2018，to May 31，2021. Among them，22 cases received IFLT，and the remaining 186 patients received CLT. Patients were divided into IFLT and CLT groups based on the type of surgery they received，and the tumor recurrence rate，early postoperative liver function indicators，incidence of complications，and other perioperative data were compared between the two groups. The primary endpoint was tumor recurrence，and secondary endpoints included early allograft dysfunction（EAD），andserum alanine aminotransferase（ALT）and aspartate aminotransferase（AST）levels. Results The recurrence-free survival period in the IFLT group was significantly higher than that in the CLT group（P ＝ 0.037）. The incidence of EAD in the IFLT group（4.5%）was significantly lower than that in the CLT group（26.3%，P ＝ 0.046）. The peak serum ALT and AST levels，as well as the peak total bilirubin levels，were all significantly lower in the IFLT group compared to the CLT group within seven days postoperatively. Conclusion IFLT technology helps avoid ischemiareperfusion injury（IRI）by maintaining the blood and oxygen supply to the liver graft，which reduces the risk of hepatocellular carcinoma（HCC）recurrence and improves the quality of the donor liver. IFLT is expected to become an effective strategy for reducing the recurrence of HCC after liver transplantation and improving patients' long-term prognosis. 

Key words:

Ischemia-reperfusion injury , Ischemia-free liver transplantation , Hepatocellular carcinoma recurrence